

HB 2300

Relating to treatments for patients with terminal diseases

HB 2300 defines terms, and institutes methods by which attending physicians may refer a patient who has a terminal disease to a health care practitioner who is authorized to treat patients with experimental drugs. The bill establishes the parameters for health care practitioners and patients eligible for treatment with experimental products, including defining the provisions for qualifying for treatment and payment.

The bill requires the physician who makes a referral, health care practitioner that administers treatment, and consulting physician to file a record with the Oregon Health Authority. Records filed by the health care practitioner that administers treatment must at least provide details that include adverse effects, positive outcomes, cost of treatment, and demographics.

The bill also requires OHA to collect, review and to track this information in order to create an annual statistical report that is available to the public.

The Capital Construction Subcommittee recommends HB 2300 be amended by the -A9 amendment, and be reported out do pass as amended.